Bayer stock forecast: Third-party price targets
Bayer (BAYN) is trading around €33.65 as of 10:48am on 4 December 2025 (UTC), moving between €33.55 and €34.60 on Capital.com’s share CFD feed. Past performance is not a reliable indicator of future results.
Bayer is trading against a backdrop of several company-specific developments, including the start of a Phase IIa clinical trial for BAY 3401016 in Alport syndrome (Business Wire, 4 December 2025) and progress in Bayer’s MRI contrast agent programme, where the company is developing the investigational compound gadoquatrane (Financial Times, 3 December 2025).
US legal proceedings related to glyphosate-based products also remain in focus, with recent comments from the Trump administration in support of Bayer’s bid to limit Roundup lawsuits adding to the wider discussion (Reuters, 2 December 2025).
Bayer stock forecast 2026–2030: Analyst price target view
Third-party Bayer price forecasts published in early-December 2025 generally cluster in the high-€20s to low-€30s over a 12-month horizon. Views differ across providers, reflecting ongoing litigation exposure, pipeline progress and balance sheet constraints.
Fintel (one-year consensus)
Fintel reports an average one-year price target of about €29.6, with estimates ranging from roughly €23.2 to €36.8. The compilation reflects multiple broker models and incorporates uncertainty around earnings, litigation costs and leverage metrics as analysts reassess Bayer’s outlook (Fintel, 4 December 2025).
Simply Wall St (analyst-compiled fair value)
Simply Wall St shows a consensus price target of around €31.2 per share. The update follows refreshed forecasts after Bayer’s guidance and third-quarter 2025 results, with analysts modelling gradual profit recovery and potential balance sheet repair over the medium term (Simply Wall St, 2 December 2025).
Investing.com (consensus forecast)
Investing.com lists a 12-month average price prediction near €31.8, with a high estimate of about €40 and a low estimate around €23, based on projections from 19 analysts. The range highlights differing assumptions about litigation outcomes, margin trends and the execution of Bayer’s multi-year restructuring (Investing.com, 4 December 2025).
Stocksguide (target price compilation)
Stocksguide cites an average target price of about €29.6 from 25 analyst estimates, implying downside potential relative to late-November 2025 trading levels. The service notes that many models include cautious assumptions on short-term earnings and cash flow, even as some analysts point to possible longer-term recovery paths (StocksGuide, 4 December 2025).
MarketWatch (ADR-based view)
For Bayer’s US-traded ADR (BAYRY), MarketWatch reports an average target of $9.33 with an “Overweight” average recommendation from 21 analyst ratings. These figures are framed around expectations for profitability and cash flow improvement over coming years, while acknowledging litigation and operational risks (MarketWatch, 4 December 2025).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
BAYN stock price: Technical overview
Bayer is trading around €33.65 as of 10:48am (UTC) on 4 December 2025, holding above its short- and medium-term moving averages. The 10/20/50/100/200-day SMAs sit near 31.3 / 29.5 / 28.3 / 28.0 / 26.1. The 14-day RSI is around 71.9, indicating elevated momentum, while the ADX near 30.7 points to a defined trend. Price also remains above the Ichimoku base line and the 20-day VWMA, both close to 30.4.
Near-term resistance stands around €32.7 (R1), with €34.9 (R2) coming into view if price closes above that zone on a sustained basis. Initial support aligns with the classic pivot near €29.2, followed by the 100-day SMA around €28.0 as the next technical area. A move below that region could bring first support near €27.0 (S1) into focus (TradingView, 4 December 2025).
This technical analysis is for information only and isn’t financial advice or a recommendation to buy or sell any instrument.
Bayer share price history
The BAYN stock price has seen a notable recovery over the past two years. The stock closed at €19.30 on 4 December 2024 after spending much of early 2025 in the high-€10s to low-€20s. From spring onwards, momentum strengthened, and by 4 December 2025 the share had closed at €33.85.
The rise from roughly €21–€23 in the first quarter of 2025 to above €30 by late November marks a clear shift from the previous year’s trading pattern. Over the full two-year period, the price has returned to levels seen in late 2023, around €33–€34, while standing materially higher year on year.
Past performance is not a reliable indicator of future results.
Capital.com analyst view
BAYN's stock price movements in 2025 moved from the low-€20s in January to the low-to-mid €30s by early December, supported by renewed attention on US legal proceedings and company-specific developments. The move follows a relatively range-bound period through much of 2024, and the recent rise has narrowed part of the gap to pre-litigation valuation territory. Even so, the share continues to respond to legal, macroeconomic and sector-level headlines.
From a fundamentals perspective, Bayer’s 2025 narrative reflects restructuring efforts, litigation exposure and pipeline updates. Management has reaffirmed guidance and highlighted contributions from newer pharmaceutical products, while analysts and rating agencies continue to flag elevated legal provisions, subdued free cash flow and execution risk around the multi-year turnaround. Court and regulatory developments could influence sentiment, although unfavourable rulings, higher-than-expected settlement costs or operational setbacks could also weigh on the outlook.
Capital.com’s client sentiment for Bayer CFDs
As of 4 December 2025, Capital.com client positioning in Bayer is currently weighted towards long exposure, with about 93.5% of open BAYN positions held by buyers versus 6.5% by sellers. This snapshot reflects active trades on the platform and may shift as clients enter or exit positions.
Summary – Bayer price 2025
- Bayer’s share price has risen from the low-€20s in early 2025 to the low-to-mid €30s by early December, including a move from €27–€28 in mid-November to the mid-€30s by month-end.
- Across two years, the share has returned to late-2023 levels in the low-€30s while standing higher year on year.
- Technical indicators show price trading above key moving averages, with a stretched RSI and a defined trend on the ADX.
- Client sentiment on Capital.com remains weighted towards long positions, with around 93.5% of open BAYN trades held by buyers.
- Third-party analyst targets commonly cluster in the high-€20s to low-€30s, reflecting ongoing uncertainty around litigation, restructuring and earnings recovery.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Bayer stock?
Bayer’s largest shareholders are typically institutional investors, including asset managers, pension funds and investment companies. Their holdings can shift as portfolios are rebalanced, and major positions are disclosed through regulatory filings in Germany. These filings report shareholdings above defined thresholds, while day-to-day ownership can vary as the stock trades in the market.
What are the 5-year Bayer stock predictions?
Long-term analyst outlooks differ significantly, as Bayer’s future performance depends on several uncertain factors such as ongoing litigation, restructuring progress, balance sheet developments and the performance of its pharmaceuticals and crop science divisions. Some analysts model potential recovery over the medium term, while others emphasise risks linked to legal costs and execution challenges. These are independent third-party opinions and shouldn’t be interpreted as predictions or guarantees.
Is Bayer a good stock to buy?
Whether a stock is suitable for you depends on your objectives, risk appetite and personal approach to trading or investing. Analysts express a range of views on Bayer, reflecting both potential recovery drivers and well-documented risks related to litigation and restructuring. It’s important to focus on factual information—such as earnings, legal updates and operational developments—without assuming any specific outcome.
Could Bayer stock go up or down?
Bayer’s share price, like all listed equities, can move in either direction. Company updates, litigation developments, sector trends in healthcare and pharmaceuticals, broader market sentiment and macroeconomic conditions can all influence short-term volatility. Historical movements and technical indicators can offer context but don’t indicate how the share will perform in the future.
Should I invest in Bayer stock?
Only you can determine whether Bayer fits your financial circumstances, risk tolerance and trading goals. Recent price movements have reflected litigation news, restructuring efforts and wider market conditions, all of which present both potential catalysts and risks. It’s important to assess these factors objectively and understand that investing in shares or trading CFDs involves the possibility of losing money.
How can I trade Bayer CFDs on Capital.com?
You can trade Bayer share CFDs on Capital.com by opening an account, completing verification and searching for Bayer (BAYN) in the platform or app. CFDs let you speculate on price movements without owning the underlying share, and you can go long or short depending on your view. Contracts for difference (CFDs) are traded on margin, and leverage amplifies both your profits and your losses.